Novo Nordisk A/S Sponsored ADR (NVO)
Novo Nordisk: The Oral Wegovy Promise
Novo Nordisk has made robust gains of 40% at the stock markets since April, supported by the success of oral Wegovy and attractive valuations. The Wegovy pill can see a nice revenue uptick in Q2 2026 going by recent data, and that can continue into the year as it gains approvals from international markets. Importantly, the pill has made gains even when competitor Eli Lilly's Foundayo has seen limited success, which can give Novo Nordisk a much-needed boost.
Novo Nordisk (NVO) Ascends While Market Falls: Some Facts to Note
Novo Nordisk (NVO) closed the most recent trading day at $51.48, moving +1.82% from the previous trading session.
NVO Stock Up on EC Approval of Wegovy Pill to Treat Obesity
Novo Nordisk wins EC approval for a once-daily oral Wegovy pill for obesity, expanding its EU franchise with the first GLP-1 tablet for weight management.
NVO Rallies 11% in a Month: How Should Investors Play the Stock?
Novo Nordisk stock gains 11% in a month as Wegovy access expands and U.K. approval boosts optimism, but rising competition and earnings pressure cloud the outlook.
Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.
Novo Nordisk launches weekly insulin Awiqli in India as diabetes burden rises
Danish drugmaker Novo Nordisk launched its weekly basal insulin injection, Awiqli, in India on Thursday, where diabetes rates are among the highest in the world.
Novo Nordisk (NVO) Dips More Than Broader Market: What You Should Know
Novo Nordisk (NVO) reached $48.89 at the closing of the latest trading day, reflecting a -1.51% change compared to its last close.
Leading bank backs European pharma as the cleaner alternative to the AI trade
UBS has reiterated its overweight stance on European pharmaceuticals, framing the sector as a more resilient home for capital than artificial intelligence at a point when the wider market is slowing. The bank argued that the investment case now rests on more than defensive quality.
2 Dirt Cheap Healthcare Stocks to Buy in July
Healthcare has become Wall Street's bargain bin in 2026, and value hunters are starting to pay attention.
Novo Nordisk: The Stock Price Is Only Beginning To Catch Up With Business Fundamentals
Novo Nordisk (NVO) is rated a BUY as business fundamentals recover faster than the stock price, driven by oral Wegovy's historic U.S. launch. NVO's oral Wegovy is expanding the obesity market, with over 3 million U.S. prescriptions in five months and 80% from GLP-1–naïve patients. Management has raised 2026 guidance, citing stronger-than-expected GLP-1 sales and international growth, with further upward revisions likely.
Novo Nordisk (NVO) Ascends While Market Falls: Some Facts to Note
In the latest trading session, Novo Nordisk (NVO) closed at $48.77, marking a +1.73% move from the previous day.
Medicare will start covering obesity drugs for the first time. Here's what patients should know
Starting Wednesday, eligible seniors with Medicare coverage can access GLP-1s for obesity with a copay of just $50 per month through a temporary program called Bridge. The move could unlock a vast new patient population for Novo Nordisk and Eli Lilly and dramatically expand access to medications that were previously out of reach for many older Americans.
